The latest Digital Dialogue from the Lab of the Future in Association with Aitia, features world-renowned presenters.
Attendance is free. You must register to attend. We reserve the right to decline registrations
  • Discovery of genetic drivers of AD: Limitation and new frontiers - Rudy Tanzi
  • Bio-Hermes dataset to enable diverse and effective clinical Trials - John Dwyer
  • Digital Twins to drive the discovery of markers for clinical trials design and next generations of breakthrough AD drugs - Colin Hill
  • Discussion and audience questions
  • 1693401296-c104c24a1c20c4eb
    Dr. Rudolph Tanzi
    Dr. Rudolph Tanzi is the Director of the Genetics and Aging Research Unit, Co-Director of the McCance Center for Brain Health, Co-Director of the MassGeneral Institute for Neurodegenerative Disease, and Vice-Chair of Neurology at Massachusetts General Hospital. He is also the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Full Biography here -
  • 1694444401-87749e4d05ed87e8
    John Dwyer
    John is the President of the Global Alzheimer’s Platform Foundation (GAP) and is a serial healthcare entrepreneur. He held his first CEO position at the age of thirty and has held leadership positions in numerous emerging growth companies in the healthcare industry. John is a co-founder of several Alzheimer’s-related groups including UsAgainstAlzheimer’s and the Alzheimer’s Action PAC, the first political action committee focused on a specific disease. John is an outspoken leader in the neurodegenerative space and is currently focusing on expanding GAP’s reach through diverse partnerships to reach the populations most likely to develop Alzheimer’s or Parkinson’s disease . Full Biography here -
  • 1693494417-5030e3c045b700d6
    Colin Hill
    CEO & Co-Founder, Aitia. Colin is a leading voice in AI and precision medicine and brings impressive leadership experience in developing and commercializing AI solutions and discoveries in biopharmaceutical drug discovery and development and in managed care industries. Colin currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non- addictive chronic pain drugs. Full Biography here -
  • 1693402105-eebb9b6ceb111574
    Luke Gibson
    Director, Open Pharma Research Ltd, Organisers of the Lab of the Future Congresses and media series